Brain Diseases
230 treatments and conditions followed through the public trial records. Not medical advice. How a status is set
Lists the pairs whose condition is this category or one beneath it. A category is not a diagnosis and not advice.
Broader: Nervous System Diseases
Narrower: Akinetic Mutism 1, Alzheimer Disease 94, Aphasia, Primary Progressive 1, Cerebral Palsy 3, Dementia 110, Drug Resistant Epilepsy 4, Epilepsies, Myoclonic 7, Epilepsies, Partial 3, Epilepsy 24, Epilepsy, Absence 2, Epilepsy, Generalized 12, Huntington Disease 7, Hydrocephalus 1, Lennox Gastaut Syndrome 1, Leukoencephalopathies 1, Lewy Body Disease 3, Migraine Disorders 23, Multiple System Atrophy 4, Myoclonic Epilepsy, Juvenile 1, Parkinson Disease 56, Persistent Vegetative State 2, Pick Disease of the Brain 1, Pseudotumor Cerebri 1, Spasms, Infantile 2, Spinocerebellar Degenerations 3
Treatments and conditions
| Treatment and condition | Where it stands | Trials |
|---|---|---|
| [F-18]Flornaptitril for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 1 mg QD to 15 mg QD PF-06649751 for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 1 mg QD to 7 mg QD PF-06649751 (if de-escalated in parent study) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 120 milligrams of ENERGI-F705 Tablets for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 15 mg QD de-escalated to 7 mg QD PF-06649751 in parent study remain at 7 mg QD for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 15 mg QD PF-06649751 for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 3 mg QD to 15 mg QD PF-06649751 for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 3 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 30mg PRAX-628 for epilepsy, generalized | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 40 Hz sound stimulation for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 40 Hz Synchronous Audio-Visual Stimulation for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 60 milligrams of ENERGI-F705 Tablets for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 7 mg QD to 15 mg QD PF-06649751 for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| 7 mg QD to 7 mg QD PF-06649751 (de-escalated in parent study) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AADvac1 for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AADvac1 for pick disease of the brain | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aav-gad for parkinson disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AB-1001 Gene Therapy for huntington disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AB-1005 for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Acetylcysteinamide for dementia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Activa PC+S Neurostimulator for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AD04 for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| AD5-NCOV for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Adaptive (Closed Loop) DBS + Intermittent Open Loop DBS + Open Loop DBS for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Adaptive (Closed Loop) DBS + Open Loop DBS for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Adaptive DBS for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 5 |
| Adaptive DBS (Activa PC+S Neurostimulator) + Continuous DBS (Activa PC+S Neurostimulator) for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| adaptive DBS (aDBS) for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| adaptive DBS delivered through AlphaDBS IPG System for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| adaptive deep brain stimulation + conventional deep brain stimulation for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| aDBS-Extended (Medtronic Percept™) for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Administer Leqemi 10 mg/kg, every two weeks. for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Aducanumab for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Agilik for cerebral palsy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Agilik + standard care for cerebral palsy | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Allay Lamp for migraine disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ambroxol for dementia | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ambroxol for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ambroxol hydrochloride for lewy body disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| apomorphine infusion for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATLAS 2030 exoskeleton for cerebral palsy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ATTN201 Focused Ultrasound to the CMN for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Atuzaginstat for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Audiovisual stimulation VR system for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| autologous dopaminergic cell implantation for parkinson disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Autologous midbrain dopamine neurons for parkinson disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BBB opening for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bexicaserin for epilepsies, myoclonic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BIIB122 for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BIIB122 225 mg for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Blood Brain Barrier (BBB) Disruption for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Blood sampling for microRNA testing for migraine disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Bocunebart for migraine disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| BR005-036C for migraine disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Brivaracetam for epilepsy, absence | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Buntanetap for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Buntanetap tartrate for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Cannabidiol for drug resistant epilepsy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cannabidiol for epilepsies, myoclonic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Cannabidiol for epilepsy | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Cannabidiol for epilepsy, absence | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Cannabidiol for lennox gastaut syndrome | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Cannabidiol for spasms, infantile | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| CapeOX + bevacizumab + PD-1 Inhibitors + SBRT for spinocerebellar degenerations | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cenobamate (syrup) for 2 to < 18 year olds + Cenobamate (tablet) for 12 to < 18 year olds for epilepsies, partial | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cervical Lymphatic Microsurgery for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Cervical Lymphaticovenous and Lymph Node-to-Vein Anastomosis for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Closed-loop stimulation + GPi alone + STN + GPi + STN alone for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Combined metabolic activators for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Communication Bridge™ for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Communication Bridge™ for aphasia, primary progressive | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CUE1 for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CUE1 non-invasive device for multiple system atrophy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CUE1 non-invasive device for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| CVN424 150 mg for parkinson disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| CVN424 75 mg for parkinson disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Daoib for dementia | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DC-LVA treatment plus usual care for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Brain Stimulation, DBS for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep cervical lymph node to venous bypass (DCLNV-BP) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep cervical lymphatic-venous anastomosis for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep cervical lymphatic-venous anastomosis, LVA for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical Lymphaticovenous Anastomosis(DLVA) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical Lymphaticovenous Anastomosis(DLVA) for lewy body disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical Lymphaticovenous Anastomosis(DLVA) for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical lymphatlc-Venous Anastomosis Surgery for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep cervical lymphovenous anastomosis (LVA) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Deep Cervical Lymphovenous Anastomosis + Routine Treatment for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Device-only fitting for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Device: Directional Deep Brain Stimulation for epilepsy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Diet + Exercise + Meditation for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donanemab for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 10 |
| Donanemab for lewy body disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donanemab + 2-Pyrazinecarboxamide, N-[3-[(4aR,7aS)-2-amino-6-(5-fluoro-2-pyrimidinyl)-4a,5,6,7-tetrahydropyrrolo[3,4-d][1,3]thiazin-7a(4H)-yl]-4-fluorophenyl]-5-methoxy- for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donanemab + Dexamethasone for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Donanemab + Nivegacetor for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| DSP-1083 implantation for parkinson disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Elismetrep for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Emestedastat for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Eptinezumab for migraine disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Erenumab for epilepsy | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Erenumab for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 22 |
| Erenumab + calcitonin gene-related peptide for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Erenumab 70 mg + GALCANEZUMAB + ATOGEPANT + EPTINEZUMAB for migraine disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Erenumab matching placebo + ERENUMAB for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Erenumab-Aooe 140 MG/ML [Aimovig] for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Etanercept for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| ETX101 for epilepsies, myoclonic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| ExAblate 4000 Type 2.1 for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exablate Model 4000 Type 2 + ADUCANUMAB + LECANEMAB for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Exenatide for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Exogenous ketone ester for drug resistant epilepsy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Facilitate tDCS + CR for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fasudil for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Fetoscopic repair of spina bifida for hydrocephalus | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| FLUOROETHOXYBENZOVESAMICOL F-18 for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Focused Transcranial Ultrasound for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Focused Transcranial Ultrasound for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Galcanezumab for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Galcanezumab + erenumab + fremanezumab for migraine disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GALCANEZUMAB + Ubrogepant for migraine disorders | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Gam-COVID-Vac for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GammaSense Stimulation device for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Gantenerumab for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| GENUS device (Active Settings) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Green light for migraine disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| GV-971 for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| GV-971 + MEMANTINE for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High doses of Thiamine y Biotin for huntington disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| High-Intensity Aerobic Exercise (AE) for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| human Mesenchymal Stem Cells for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Iluzanebart for leukoencephalopathies | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intermittent theta burst stimulation (iTBS) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intermittent theta burst stimulation (iTBS) + METHYLPHENIDATE HYDROCHLORIDE for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| intra-striatal rAAV5-miHTT for huntington disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| ION337 for epilepsies, myoclonic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| IPILIMUMAB + SINTILIMAB + Cetuximab + DABRAFENIB for spinocerebellar degenerations | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| JNJ-64042056 for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| JZP926 capsule for myoclonic epilepsy, juvenile | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Ketamine for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lecanemab for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| LECANEMAB + Etalanetug for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| lentiviral gene therapy for drug resistant epilepsy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lidocaine for migraine disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lifus for epilepsy | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lifus for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Lixisenatide for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| low intensity focused ultrasound (LIFU) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY-2599666 for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY3002813 for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY3002813-IV for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY3002813-SC for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| LY3884961 + Sirolimus + Methylprednisolone for parkinson disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents + Neuronavigation-guided single-element focused ultrasound transducer + Positron Emission Tomography (PET) + FLORBETAPIR F-18 + PERFLUTREN for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Matching Placebo (E2814) + LECANEMAB for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Memantine for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Metformin for parkinson disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Mevidalen for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MK-1167 for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| ML-007C-MA for brain diseases | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Moderate doses of Thiamine y Biotin for huntington disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Modified deep cervical Lymphatic-Venous Anastomosis for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Modified deep cervical Lymphatic-Venous Anastomosis for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| MR guided low intensity focused ultrasound for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NanoLithium® NP03 for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nicotinamide Riboside (NR) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Nivegacetor for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| NMS-01 for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Obicetrapib 10 mg for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Onabotulinumtoxin-A for migraine disorders | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Opakalim for drug resistant epilepsy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Opakalim for epilepsies, partial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| PBT-434 for multiple system atrophy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PEMBROLIZUMAB + Porustobart for spinocerebellar degenerations | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Percept™ PC and Percept RC with Adaptive DBS (aDBS™) for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-06649751 high dose (15 mg QD) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-06649751 low dose (1 mg QD) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-06649751 middle dose 1 (3 mg QD) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| PF-06649751 middle dose 2 (7 mg QD) for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo for migraine disorders | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Placebo for parkinson disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + ADUCANUMAB for alzheimer disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Placebo + Donanemab for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + Psilocybin for migraine disorders | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Placebo + SRP-1005 for huntington disease | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Placebo + TAVAPADON + TRIMETHOBENZAMIDE HYDROCHLORIDE for parkinson disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Prasinezumab for parkinson disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| PRT-064040 nasal spray for migraine disorders | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Psilocybin for migraine disorders | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Psilocybin for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| Psilocybin + PIMAVANSERIN for parkinson disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| RAP-219 for epilepsies, partial | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Receive tDCS+CR for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant varicella zoster virus glycoprotein e antigen for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Recombinant varicella zoster virus glycoprotein e antigen for dementia | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Relutrigine for spasms, infantile | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| REPAIR Sleep for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Semagludtide for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Service-only Fitting for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Simufilam for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 6 |
| Sodium oligo-mannurarate 600mg for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium oligo-mannurarate 900mg for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Sodium Oligomannate Capsules for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Solanezumab for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| Stent Implantation for pseudotumor cerebri | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| stimulation device for akinetic mutism | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| stimulation device for persistent vegetative state | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| STK-001 - Single Ascending Doses for epilepsies, myoclonic | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Supermicrosurgical Lymphaticovenular Anastomosis (LVA) for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| tACS combined with 40 Hz sound stimulation for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tavapadon for parkinson disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 7 |
| TEV-56286 for multiple system atrophy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 2 |
| The LFP Beta aDBS System for parkinson disease | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Tominersen for huntington disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 4 |
| Transcranial alternating current stimulation for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Transcranial Direct Current Stimulation for migraine disorders | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| transcranial magnetic resonance guided focused ultrasound BBB disruption for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| tributyrin for alzheimer disease | Trial registered, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Troculeucel for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Trontinemab for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
| Ubrogepant + ERENUMAB for migraine disorders | Phase 1 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Vagus nerve stimulation; for persistent vegetative state | Trials ended early, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valacyclovir for alzheimer disease | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Valiltramiprosate for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Votoplam (blinded) for huntington disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Wujia Yizhi granules for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Xanomeline Enteric Capsule + Xanomeline/Trospium Chloride Capsule for alzheimer disease | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| YA-101 for multiple system atrophy | Phase 2 trial, as of 19 Nov 2026 (not yet checked by a person) | 1 |
| Zorevunersen for epilepsies, myoclonic | Phase 3 trial, as of 19 Nov 2026 (not yet checked by a person) | 3 |
Categories are from Medical Subject Headings (MeSH), U.S. National Library of Medicine, courtesy of the U.S. National Library of Medicine: MeSH. They may not reflect the most current data available from NLM. NLM does not endorse this site.